Regeneron

EMC-IRB-25-046

ROXI-ASPEN: A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate Cenvacibart (REGN7508), a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid (aspirin) for Prophylaxis of Symptomatic Venous Thromboembolism (VTE) After Elective Total Knee Arthroplasty (TKA)